Medical Policy Update for January 4, 2022
| Policy Name | Updated Criteria |
| Omalizumab (Xolair®) | Added requirement for use of the self-administered product unless certain criteria are met. For nasal polyposis indication: added requirement of step through Xhance, removed requirement for nasal saline irrigations, and added requirement for previous surgery for nasal polyps. Adjusted criteria for chronic rhinosinusitis with nasal polyposis to allow for patients who are not a candidate for sinus surgery. |
Blue Connect